| CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma
|
(CuraGen)
|
11-Jun-2008 |
| Cytokinetics to Present Clinical Data on CK-1827452, a Selective Cardiac Myosin Activator, at the 2008 Heart Failure Congress of the European Society of Cardiology
|
(Cytokinetics)
|
09-Jun-2008 |
| InteKrin Therapeutics Presents Phase 2a Data at American Diabetes Association Meeting for INT131, a Non-TZD SPPARM
|
(InteKrin Therapeutics)
|
08-Jun-2008 |
| Twists and turns continue in Promacta vs. Nplate race
|
(Ligand Pharmaceuticals)
|
02-Jun-2008 |
| New Pfizer Data Presented on CP-751,871 Across Non-Small Cell Lung Cancer and Ewing’s Sarcoma
|
(Pfizer)
|
02-Jun-2008 |
| Updated Data from Ongoing Phase 3 Trials Support the Continued Study of Vectibix(R) (panitumumab) in Combination with Standard Chemotherapy
|
(Amgen)
|
01-Jun-2008 |
| CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
|
(CuraGen)
|
01-Jun-2008 |
| Interim Phase 2 Results of Open-Label Clinical Trial of Denosumab in Giant Cell Tumor of Bone Demonstrated 87 Percent Response Rate
|
(Amgen)
|
31-May-2008 |
| Amgen Reports Positive Data at ASCO from Three Studies of Denosumab in Cancer Patients
|
(Amgen)
|
31-May-2008 |
| Amgen Presents New Data at ASCO on Four Investigational Molecules from Oncology Pipeline
|
(Amgen)
|
31-May-2008 |
| Clarification on Press Release Issued Earlier Today: Targeted Genetics Confirms Positive, Interim Phase 1/2 Study Findings
|
(Targeted Genetics)
|
30-May-2008 |
| Targeted Genetics Reports Additional Data From Inflammatory Arthritis Clinical Trial
|
(Targeted Genetics)
|
30-May-2008 |
| Negative Promacta review causes re-think in race with Nplate
|
(Ligand Pharmaceuticals)
|
29-May-2008 |
| Denosumab Achieved Superior Bone Mineral Density Gains in Head-to-Head Trial Versus Weekly Alendronate (FOSAMAX(R))
|
(Amgen)
|
28-May-2008 |
| Denosumab Osteoporosis Study Meets Primary and All Secondary Bone Mineral Density Endpoints in Alendronate (FOSAMAX(R)) Transition Study
|
(Amgen)
|
19-May-2008 |
| Amgen Highlights Data to be Presented at ASCO
|
(Amgen)
|
15-May-2008 |
| Amgen to Participate in Dermatologic and Ophthalmic Drugs Advisory Committee Meeting in June
|
(Amgen)
|
01-May-2008 |
| Cytokinetics Announces the Initiation of Second Phase IIa Clinical Trial of CK-1827452
|
(Cytokinetics)
|
29-Apr-2008 |
| DART Study Results Demonstrate Dose Escalation With Enbrel(R)(etanercept) is Significantly Lower Than Other Commonly Used Anti-TNF Agents in Patients With Rheumatoid Arthritis(1)
|
(Wyeth)
|
24-Apr-2008 |
| Amgen Presents Preclinical and Clinical Data from Oncology Programs
|
(Amgen)
|
15-Apr-2008 |
| U3 Pharma Achieves Preclinical Proof of Concept for U3-1287 (AMG 888)
|
(U3 Pharma)
|
14-Apr-2008 |
| Early Data on Amgen's Anti-Angiogenesis AMG 386 Preclinical Data Suggests Greater Reduction in Tumor Growth when Angiopoietin 1/2 and VEGF Pathways are Both InhibitedPipeline Molecules Suggest Biologic Activity Across Tumor Types
|
(Amgen)
|
13-Apr-2008 |
| CuraGen Advances CR011-vcMMAE into Phase II
|
(CuraGen)
|
09-Apr-2008 |
| Amgen Statement on Romiplostim PDUFA Date
|
(Amgen)
|
08-Apr-2008 |
| Pivotal Phase 3 Data Show Denosumab Increased Bone Density at Multiple Skeletal Sites in Early and Later Stage Postmenopausal Women
|
(Amgen)
|
02-Apr-2008 |
| Cytokinetics Announces Positive Results from an Interim Analysis of an Ongoing Phase IIa Clinical Trial of CK-1827452 in Patients with Stable Heart Failure
|
(Cytokinetics)
|
24-Mar-2008 |
| Targeted Genetics Announces Completion of Dosing for the Phase 1/2 Clinical Trial of tgAAC94 for Inflammatory Arthritis
|
(Targeted Genetics)
|
18-Mar-2008 |
| Amgen and Wyeth Announce Updates to U.S. Prescribing Information for Enbrel
|
(Wyeth)
|
17-Mar-2008 |
| Amgen and Wyeth Announce Updates to U.S. Prescribing Information for Enbrel(R)
|
(Amgen)
|
17-Mar-2008 |
| Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
|
(Nuvelo)
|
17-Mar-2008 |
| Amgen Statement on Successful Outcome of Romiplostim Panel Meeting
|
(Amgen)
|
12-Mar-2008 |
| Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs
|
(Memory Pharmaceuticals)
|
12-Mar-2008 |
| Amgen to Discuss Romiplostim Application at FDA ODAC Meeting
|
(Amgen)
|
12-Mar-2008 |
| Amgen Announces Update to U.S. Prescribing Information for Aranesp(R) and EPOGEN(R)
|
(Amgen)
|
07-Mar-2008 |
| Ortho Biotech Modifies Prescribing Information for PROCRIT® (Epoetin alfa)
|
(Johnson & Johnson)
|
07-Mar-2008 |
| EU Commission Approves Updated Prescribing Information for Aranesp(R)
|
(Amgen)
|
05-Mar-2008 |
| InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
|
(InteKrin Therapeutics)
|
25-Feb-2008 |
| Teva's Developed G-CSF is the First Biosimilar to Receive a Positive Opinion from European Union Regulators
|
(Teva Pharmaceutical Industries)
|
21-Feb-2008 |
| New Findings Show Enbrel(R) (etanercept) Significantly Reduced Levels of C-Reactive Protein, a Marker of Inflammation, in Patients with Moderate to Severe Plaque Psoriasis
|
(Amgen)
|
01-Feb-2008 |
| New Findings Show Enbrel® (etanercept) Significantly Reduced Levels of C-Reactive Protein, a Marker of Inflammation, in Patients with Moderate to Severe Plaque Psoriasis
|
(Wyeth)
|
01-Feb-2008 |
| Pooled Phase 3 Study of Nplate(TM) (Romiplostim) in Adult Patients with Chronic ITP Published in The Lancet
|
(Amgen)
|
31-Jan-2008 |
| Amgen Statement on Aranesp Manuscript in the Journal of Clinical Oncology
|
(Amgen)
|
28-Jan-2008 |
| Interim Safety Data Presented on Vectibix(TM) (Panitumumab) in Combination with Standard Chemotherapy
|
(Amgen)
|
27-Jan-2008 |
| KRAS Gene Status May Impact Vectibix(TM) (Panitumumab) Efficacy and Patient Reported Outcomes in Advanced Colorectal Cancer Patients
|
(Amgen)
|
24-Jan-2008 |
| Denosumab Osteoporosis Study Met Primary and All Secondary Bone Mineral Density Endpoints in a Head-to-Head Comparison with Weekly Alendronate (FOSAMAX(R))
|
(Amgen)
|
24-Jan-2008 |
| Nuvelo Announces Results from Phase 3 NAPA Program in Acute Peripheral Arterial Occlusion
|
(Nuvelo)
|
24-Jan-2008 |
| New Study Reports Enbrel(R) (Etanercept) Significantly Improved Moderate to Severe Plaque Psoriasis in Children and Adolescents
|
(Amgen)
|
16-Jan-2008 |
| New Study Shows Biologic Therapy Enbrel(R) (etanercept) Effective in Treating Psoriasis in Children and Adolescents
|
(Wyeth)
|
16-Jan-2008 |
| Medarex to Receive Milestone Payment from Amgen
|
(Medarex)
|
18-Dec-2007 |
| Denosumab brightens Amgen’s outlook
|
(Amgen)
|
17-Dec-2007 |
| Pivotal Phase 3 Data Show Denosumab Increased Bone Density Throughout Skeleton in Non-Metastatic Breast Cancer Patients on Adjuvant Aromatase Inhibitor Therapy
|
(Amgen)
|
14-Dec-2007 |
| Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke
|
(Nuvelo)
|
12-Dec-2007 |
| Promacta looks surer bet than Nplate
|
(GlaxoSmithKline)
|
11-Dec-2007 |
| Pivotal Phase 3 NPLATE(TM) Study in Non-Splenectomized Patients Met Primary Endpoints
|
(Amgen)
|
10-Dec-2007 |
| Nuvelo Phase 3 SONOMA-2 Trial Shows Alfimeprase has the Potential to Restore Catheter Function
|
(Nuvelo)
|
09-Dec-2007 |
| Pivotal Phase 3 Romiplostim Study in Splenectomized Patients Meets Primary Endpoints
|
(Amgen)
|
08-Dec-2007 |
| Amgen in Discussions with FDA to Update U.S. Prescribing Information for ESAs
|
(Amgen)
|
06-Dec-2007 |
| Vectibix(R) Approved in the European Union for the Treatment of Metastatic Colorectal Cancer
|
(Amgen)
|
05-Dec-2007 |
| Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Assessment of Its Phase I/II Trial of tgAAC94 for Inflammatory Arthritis
|
(Targeted Genetics)
|
03-Dec-2007 |
| Amgen Announces Interim Results of Aranesp(R) ''PREPARE'' Study in Breast Cancer Patients
|
(Amgen)
|
30-Nov-2007 |
| Targeted Genetics Announces That FDA Has Removed Hold on Phase I/II Clinical Trial of tgAAC94 for Inflammatory Arthritis
|
(Targeted Genetics)
|
26-Nov-2007 |
| Insmed Advances Follow on Biologics Initiative
|
(Insmed)
|
13-Nov-2007 |
| Targeted Genetics Announces Positive Interim Phase I/II Results for tgAAC94 in Inflammatory Arthritis
|
(Targeted Genetics)
|
10-Nov-2007 |
| New Data Show That Half of Patients with Active Early Rheumatoid Arthritis Achieved Clinical Remission at One Year When Treated with Enbrel(R) (etanercept) Plus Methotrexate
|
(Amgen)
|
07-Nov-2007 |
| CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
|
(CuraGen)
|
24-Oct-2007 |
| Amgen Provides Update on Late-Stage and Early-Stage Pipeline at UBS Global Life Sciences Conference
|
(Amgen)
|
28-Sep-2007 |
| Aranesp(R) (darbepoetin alfa) Approved for Use in All European Paediatric Patients with Chronic Renal Failure Anaemia
|
(Amgen)
|
28-Sep-2007 |
| Amgen Receives Proposal for Amending EU Prescribing Information for Aranesp(R)
|
(Amgen)
|
27-Sep-2007 |
| New Analysis Suggests First Cycle Use of Neulasta(R) Reduces Febrile Neutropenia Hospitalizations and Chemotherapy Dose Reductions in Breast Cancer Patients Compared to Current Practice
|
(Amgen)
|
26-Sep-2007 |
| Phase 2 Study Suggests That Extended Dosing of Aranesp(R) is as Efficacious as Weekly Dosing
|
(Amgen)
|
26-Sep-2007 |
| New Biomarker Data Links KRAS Gene to Vectibix(TM) Clinical Response
|
(Amgen)
|
25-Sep-2007 |
| Vectibix(TM) (panitumumab) Receives Positive Opinion for Marketing Authorization in the European Union
|
(Amgen)
|
21-Sep-2007 |
| Amgen Oncology Highlights Upcoming Data Presentations at the 2007 European Conference on Clinical Oncology
|
(Amgen)
|
21-Sep-2007 |
| Cytokinetics to Present Data on Selective Cardiac Myosin Activator CK-1827452 at the 2007 Annual Heart Failure Society of America Meeting
|
(Cytokinetics)
|
10-Sep-2007 |
| Aranesp(R) Study Showing No Negative Impact on Survival in SCLC Presented at World Conference on Lung Cancer
|
(Amgen)
|
06-Sep-2007 |
| Sandoz Receives European Commission Approval for Biosimilar Epoetin Alfa
|
(Novartis)
|
31-Aug-2007 |
| Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
|
(Nuvelo)
|
22-Aug-2007 |
| ENBREL Safety Data for up to Eight Years in Patients with Juvenile Rheumatoid Arthritis Being Presented at EULAR
|
(Amgen)
|
13-Jun-2007 |
| Enbrel Safety Data for up to Eight Years In Patients with Juvenile Rheumatoid Arthritis Being Presented at EULAR
|
(Wyeth)
|
13-Jun-2007 |
